MD Anderson Cancer Center, Department of Leukemia
Welcome,         Profile    Billing    Logout  
 17 Trials 
26 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Verstovsek, Srdan
MOMENTUM, NCT04173494 / 2019-000583-18: A Study of Momelotinib Versus Danazol in Symptomatic and Anemic Myelofibrosis Participants

Checkmark New data from MOMENTUM trial in myelofibrosis at ASH 2022
Dec 2022 - Dec 2022: New data from MOMENTUM trial in myelofibrosis at ASH 2022
Checkmark Data for myelofibrosis at ASCO 2022 based on from MOMENTUM trial
May 2022 - May 2022: Data for myelofibrosis at ASCO 2022 based on from MOMENTUM trial
Checkmark Results for symptomatic and anemic 2L Myelofibrosis based on MOMENTUM study at ASCO 2022
More
Completed
3
195
Europe, Canada, US, RoW
Momelotinib, MMB, GS-0387, CYT387, Placebo to match danazol, Danazol, Danocrine, Placebo to match momelotinib
Sierra Oncology LLC - a GSK company
Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
12/21
12/22
SURPASS ET, NCT04285086: Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance

Active, not recruiting
3
174
Canada, Japan, US, RoW
Ropeginterferon alfa-2b, P1101, Anagrelide
PharmaEssentia, Medpace, Inc., EPS International, Brightech International
Essential Thrombocythemia
11/24
12/25
MYLOX-1, NCT04679870: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral GB2064 in Participants With Myelofibrosis

Active, not recruiting
2
21
Europe, US, RoW
GB2064
Galecto Biotech AB, OPIS s.r.l
Myelofibrosis
12/23
06/26
Jain, Nitin
NCI-2016-00797, NCT02756897: Venetoclax and Ibrutinib in Treating Patients With Chronic or Small Lymphocytic Leukemia

Active, not recruiting
2
234
US
Ibrutinib, BTK Inhibitor PCI-32765, CRA-032765, Imbruvica, PCI-32765, Laboratory Biomarker Analysis, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta, Venclyxto
M.D. Anderson Cancer Center
Chronic Lymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Small Lymphocytic Lymphoma, Small Lymphocytic Lymphoma
07/24
07/24
NCT05025787: A Study to Evaluate the Safety and Efficacy of CNTX-6970 in Subjects With Knee Osteoarthritis Pain.

Completed
2
77
US
CNTX-6970, Placebo
Maurizio Fava, MD
Knee Osteoarthritis
06/24
06/24
NCT03054896: A Phase II Study of Venetoclax in Combination With Dose-adjusted EPOCH-R or R-CHOP for Patients With Richter's Syndrome

Recruiting
2
67
US
Venetoclax, Venclexta, DA-EPOCH-R, R-CHOP
Dana-Farber Cancer Institute, Genentech, Inc.
Richter Syndrome
12/24
12/27
NCT02846623: Atezolizumab, Obinutuzumab, and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Relapsed or Refractory Richter Syndrome

Recruiting
2
65
US
Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG7446, RO5541267, Tecentriq, Laboratory Biomarker Analysis, Obinutuzumab, Anti-CD20 Monoclonal Antibody R7159, GA-101, GA101, Gazyva, huMAB(CD20), R7159, RO 5072759, RO-5072759, RO5072759, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta, Venclyxto
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Chronic Lymphocytic Leukemia, Recurrent Transformed Chronic Lymphocytic Leukemia, Refractory Transformed Chronic Lymphocytic Leukemia, Richter Syndrome, Small Lymphocytic Lymphoma
02/25
02/25
NCT02629809: Ibrutinib, Fludarabine Phosphate, Cyclophosphamide, and Obinutuzumab in Treating Patients With Chronic Lymphocytic Leukemia

Active, not recruiting
2
81
US
Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Fludarabine Phosphate, 2-F-ara-AMP, 9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)-, Beneflur, Fludara, SH T 586, Ibrutinib, BTK Inhibitor PCI-32765, CRA-032765, Imbruvica, PCI-32765, Obinutuzumab, Anti-CD20 Monoclonal Antibody R7159, GA-101, GA101, Gazyva, huMAB(CD20), R7159, RO 5072759, RO-5072759, RO5072759
M.D. Anderson Cancer Center
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
03/25
03/25
NCI-2022-07625, NCT05536349: Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)

Recruiting
2
60
US
Pirtobrutinib, Obinutuzumab, GA101, Gazyva, RO5072759, Venetoclax, ABT-199, GDC-0199, Valacyclovir, Allopurinol
M.D. Anderson Cancer Center, Loxo Oncology, Inc., The Leukemia and Lymphoma Society
Leukemia
04/25
04/25
PBCAR0191-01, NCT03666000: Dose-escalation, Dose-expansion Study of Safety of PBCAR0191 in Patients With r/r NHL and r/r B-cell ALL

Recruiting
1/2
120
US
PBCAR0191, Allogeneic Anti-CD19 CAR T cells, Fludarabine, Cyclophosphamide
Imugene Limited
Non-Hodgkin Lymphoma, B-cell Acute Lymphoblastic Leukemia
03/24
06/24
BALLI-01, NCT04150497: Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia

Recruiting
1/2
40
Europe, US
UCART22, CLLS52, Alemtuzumab
Cellectis S.A.
B-cell Acute Lymphoblastic Leukemia
12/23
01/26
NCT03492125: A Study Of The Selective PKC-β Inhibitor MS- 553

Recruiting
1/2
117
US
MS-553, acalabrutinib, venetoclax, Venclexta, Venclyxto, Rituximab, Rituxan, MabThera, obinutuzumab, Gazyva
MingSight Pharmaceuticals, Inc
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Aggressive Lymphoma
04/24
06/24
NCT03319901: Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL

Recruiting
1/2
82
US
Venetoclax, ABT199, Standard Chemotherapy
Dana-Farber Cancer Institute, AbbVie
Leukemia
04/26
04/27
NCI-2018-02016, NCT03698552: ADCT-602 in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia

Recruiting
1/2
65
US
ADCT-602, ADCT-602 (CN); hLL2-cys-PBD (SY); ADCT602 (CN); ADCT 602 (CN); hLL2-cys-SG3249 (SY); ; ADC ADCT-602
M.D. Anderson Cancer Center, National Cancer Institute (NCI), ADC Therapeutics S.A.
Blasts 5 Percent or More of Bone Marrow Nucleated Cells, CD22 Positive, Philadelphia Chromosome Positive, Recurrent B Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia
12/25
12/25
CYTB323A12101, NCT03960840: Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, ALL and 1L HR LBCL

Recruiting
1/2
225
Europe, Japan, US, RoW
Rapcabtagene autoleucel single agent, Ibrutinib
Novartis Pharmaceuticals
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Diffuse Large B-cell Lymphoma, Acute Lymphoblastic Leukemia, Large B-cell Lymphoma
06/27
06/27
NCT05275504: Study to Evaluate the Safety and Tolerability of TT-01488 in Patients With B-Cell Malignancies

Recruiting
1
37
US
TT-01488
TransThera Sciences (Nanjing), Inc.
B-Cell Malignancies
09/22
04/23
NIMBLE, NCT04865419: Study of AZD0466 Monotherapy or in Combination in Patients With Advanced Haematological Malignancies

Terminated
1
46
Europe, US, RoW
AZD0466, Voriconazole
AstraZeneca
Haematological Malignancies
08/23
08/23
NCT05961696: A Phase I Study of Mosunetuzumab for Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia

Withdrawn
1
22
US
Mosunetuzumab, RO7030816
M.D. Anderson Cancer Center, Genentech, Inc.
Refractory B-cell Acute Lymphoblastic Leukemia
10/23
10/23
NCT04781855: Ipilimumab, Ibrutinib, and Nivolumab for the Treatment of Chronic Lymphocytic Leukemia and Richter Transformation

Active, not recruiting
1
50
US
Ibrutinib, BTK Inhibitor PCI-32765, CRA-032765, Imbruvica, PCI-32765, Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, Ipilimumab Biosimilar CS1002, MDX-010, MDX-CTLA4, Yervoy, Nivolumab, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo
M.D. Anderson Cancer Center
Hematopoietic and Lymphoid Cell Neoplasm, Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Small Lymphocytic Lymphoma, Richter Syndrome
12/24
12/24
C1763102, NCT05602363: AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma

Recruiting
1
110
US
AS-1763
Carna Biosciences, Inc.
B-cell Malignancy, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Waldenstrom Macroglobulinemia, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Follicular Lymphoma, Non-Hodgkin Lymphoma
09/27
09/27
NCT03752619: Peripheral Nerve Stimulation(PNS) for Subacromial Impingement Syndrome(SIS)

Active, not recruiting
N/A
116
US
Contracting Producing Peripheral Nerve Stimulation, Intramuscular Peripheral Nerve Stimulation, Intramuscular Electrical Nerve Stimulation, SMARTPATCH System, Non Contracting Producing Peripheral Nerve Stimulation, Physical Therapy
MetroHealth Medical Center, University of Texas
Shoulder Pain, Shoulder Impingement Syndrome, Shoulder Tendinitis, Shoulder Bursitis, Pain, Shoulder
08/24
08/24
NCT02287090: Comparative Effectiveness of Operative Versus Non-Operative Treatments for Rotator Cuff Tears

Active, not recruiting
N/A
400
US
Observational Cohort
Vanderbilt University Medical Center, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Brigham and Women's Hospital, Orthopedic Institute, Sioux Falls, SD, University of Texas
Rotator Cuff Tear
12/24
12/24
ARC, NCT03295994: Operative Versus Non-Operative Treatment for Atraumatic Rotator Cuff Tears

Recruiting
N/A
180
US
Operative, Non-Operative
University of Texas Southwestern Medical Center, Patient-Centered Outcomes Research Institute, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Rotator Cuff Tear
12/24
06/25
NCT04831164: Genetic Epidemiology of Rotator Cuff Tears: The cuffGEN Study

Recruiting
N/A
1500
US
NA (not an interventional study)
University of Texas Southwestern Medical Center, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Rotator Cuff Tears
12/26
12/31
Allred, Sheri L
NCT03492125: A Study Of The Selective PKC-β Inhibitor MS- 553

Recruiting
1/2
117
US
MS-553, acalabrutinib, venetoclax, Venclexta, Venclyxto, Rituximab, Rituxan, MabThera, obinutuzumab, Gazyva
MingSight Pharmaceuticals, Inc
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Aggressive Lymphoma
04/24
06/24
CIRLL study, NCT03420183: A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies

Recruiting
1b
156
US
Cirmtuzumab followed by Cirmtuzumab plus ibrutinib, UC-961, Imbruvica, Cirmtuzumab plus ibrutinib, Ibrutinib
Oncternal Therapeutics, Inc, University of California, San Diego, California Institute for Regenerative Medicine (CIRM)
B-cell Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle-cell Lymphoma
04/19
12/22

Download Options